Biosimilars are new biological medicines that are highly similar but not identical to their reference biological medicines. As biosimilars are produced from living organisms by genetic engineering, even a small difference in their production process has the potential to alter their efficacy and safety. Therefore, prior to their approval, biosimilars are assessed to confirm therapeutic equivalence and comparable safety and efficacy to their biological reference medicines. Once approved, adverse effects of biosimilars are continuously monitored by regulatory bodies. The lower cost of biosimilars improves affordability and access to new therapies for patients with serious diseases and these medicines are increasingly being prescribed in Australia. Hence, pharmacy professionals need to be aware of the structural complexity and important aspects of the regulatory approval process, immunogenicity and safety profiling, extrapolation of indication, nomenclature and labelling, interchangeability and substitution for these novel therapies.
Biologics are being increasingly used for serious immune-mediated inflammatory chronic conditions. 1 Despite the benefits of biologic therapies, patient access to these therapies is suboptimal due to their high cost. [2] [3] [4] Biosimilars are less expensive since the cost of the original research and development has less effect on price, potentially offering increased patient access to these therapies. 1 However, due to their complex structure and manufacturing process, biosimilars, unlike generic traditional small molecule medications, are not identical to their reference biologic and require comparative analytical and clinical studies to confirm that no clinically meaningful differences exist to their reference products. 4 Consistent with their comparator reference products, immunological testing and pharmacovigilance strategies are required to monitor for immunogenicity and safety. 2, 4 This paper reviews basic information about the structural complexity of biologics and biosimilars, regulatory approval processes, immunogenicity and safety profiling, as well as issues related to extrapolation of indication, nomenclature, interchangeability and substitution.
BIOLOGICS Synonyms: Biological Medicinal Products, Biotechnological Products, Biologic Therapies
Biologics are used for the treatment of chronic inflammatory and immune diseases and for the treatment and supportive care of cancer and other diseases. They include products such as: 1 recombinant human hormones, cytokines and growth factors (e.g. erythropoietin, insulin, granulocyte colony-stimulating factor, human growth hormone) 2 monoclonal antibodies (the mAbs) e.g. trastuzumab, infliximab (INX) 3 fusion proteins, e.g. etanercept, and 4 antibody plus drug combinations such as trastuzumab plus emtansine (Kadcyla). 1, 2 Biologics include genetically engineered derived proteins produced from biological sources, such as yeasts, bacteria, blood or animal cells. They have more complex structures than traditional medicines and different batches of the same biologic medicine can vary, such that the creation of exact copies of biological medicines is not always possible. [3] [4] [5] A biosimilar medicine is a biological product that is designed to be similar to a biological medicine that has been granted consent to be marketed (the reference biologic). Once a patent for a biological medicine has expired, a biosimilar medicine can be marketed. 1, 6, 7 Biosimilars are highly similar products with comparable safety and efficacy that are available at a lower cost and have potential to increase competition, reduce costs and improve patient access to therapies. 3 It is estimated that biosimilars cost 20-40% less than their reference products due to reduced testing requirements for approval. 8 The manufacturing process for biologics is complex and includes multiple steps: cloning, selecting, maintaining and expanding the cell line; and isolating, purifying and characterising the product. As biosimilars are produced by genetic engineering using cell lines and production processes developed by each manufacturer, even minor variations in the production process can impact the efficacy and safety of a biosimilar medicine. 8 The amino acid sequence is expected to be the same with only small differences in the glycosylation (microheterogeneity) pattern of the molecule being acceptable if there is to be no impact on safety and efficacy. 1, 4 Hence, the active substance of a biosimilar is similar, but not identical, to that of the biological reference. Consequently, the safety and efficacy of biosimilars are highly dependent on the quality and reliability of their production processes. 4 INX is the original innovator biologic, monoclonal antibody (mAb) to tumour necrosis factor-a (TNFa) that has been approved for treatment of rheumatoid diseases (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) and inflammatory bowel disease (Crohn's disease, ulcerative colitis). CT-P13 is a chimeric humanmurine biosimilar to INX. 6, 9 
APPROVAL PROCESS FOR BIOSIMILARS
Biosimilars are approved by regulatory authorities based on comparative analytical and clinical studies that demonstrate no clinically meaningful differences to their reference biologic. 3, 10 New biosimilar medicines undergo clinical trials to demonstrate comparable safety, quality and efficacy to an approved biologic medicine. 8, 10, 11 Regulatory approval is based on pharmacokinetic and pharmacodynamic studies as well as comparative clinical efficacy and safety studies. The following assessments are required for a biosimilar product market authorisation. 10 
Nonclinical assessment: pharmaco-toxicological assessment
In vitro studies are performed with an appropriate number of batches of the biosimilar and reference biologic to provide evidence that observed differences are not clinically relevant. These studies should include relevant assays on binding to target receptors, antigens, enzymes known to be involved in the pharmaco-toxicological effects and pharmacokinetics (PK) of the reference product. 10 In vivo studies may be conducted when qualitative or quantitative differences or new potentially relevant differences are detected in in vitro studies.
2 Clinical assessment: PK, pharmcodynamic and efficacy studies
Comparative PK studies should demonstrate a similar PK profile for the biosimilar and the reference biologic.
As most monoclonal antibodies demonstrate nonlinear, dose-dependent PK, single-dose PK studies using low and high-dose levels for comparing elimination are preferred to repeat-dose studies.
12 Pharmacodynamic markers should be added to PK studies. 10 The purpose of efficacy studies is to confirm comparable clinical performance of the biosimilar and the reference product. Adequately powered, phase 3, randomised, parallel group comparative clinical trials, preferably double-blind, incorporating an equivalence design, in a population representative of an approved Safety considerations include immunogenicity, hypersensitivity reactions and increased risk for other adverse reactions. Comparative safety data is collected preauthorisation and duration of safety follow-up should be justified. The type, severity and frequency of the adverse reactions between the biosimilar and the reference product should be compared. Risk assessment of the anticipated specific risk for the biosimilar should be provided in the application dossier, including description of possible safety concerns that may result from a manufacturing process different to that of the reference product, especially those related to infusion-related reactions and immunogenicity. 10 4 Pharmacovigilance assessment Due to their complexity and sensitivity to manufacturing changes, biosimilars are susceptible to structural alterations that can affect their safety. Therefore, robust post-approval safety monitoring for detection, assessment, understanding and prevention of adverse effects on an on-going basis is required. As a part of the authorisation procedure, the applicant must present a risk management plan (RMP) and pharmacovigilance guidelines. Immunogenicity should always be considered in the safety specification section of the RMP and any specific safety monitoring required for the reference biologic or product class should be adequately addressed in the pharmacovigilance plan. 4, 8, 10 Unwanted immune response is the primary safety concern. It is possible that individual patients may experience adverse effects with a biosimilar that they did not have with the reference biologic or vice versa, or from different batches of a biologic or biosimilar medicine. 1 If an adverse drug reaction to a biologic or biosimilar occurs or is suspected, a report including description of the reaction, indication, International Non-proprietary Name (INN), brand name, the AUST R number, the batch number and expiry date, the dosage form and presentation, manufacturer name and country of origin should be submitted to the Therapeutic Goods Administration (TGA). 4, 7, 8 
IMMUNOGENICITY
The potential for unforeseen adverse effects due to an immunologic reaction is a major concern with biologics and biosimilars. 4, 10, 13 The consequences of an immune reaction to a therapeutic protein range from the transient appearance of anti-drug antibodies (ADAs) without any clinical significance, to severe life-threatening conditions. Clinical consequences of immunogenicity are a lack of efficacy, pharmacokinetic alteration, development of antibodies that neutralise the product, 14 hypersensitivity, infusion reactions and development of antibodies directed toward an endogenous protein resulting in a serious adverse event.
13
The cross-reactivity of ADA to endogenous protein may have severe consequences if the reaction involves a non-redundant endogenous counterpart of the therapeutic protein. For example, severe thrombocytopaenia developed in patients treated with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) due to the development of antibodies to PEG-rHuMGDF that cross-reacted with and neutralised endogenous thrombopoietin. 15 If an endogenous protein is redundant in biological function, any cross-reactivity reaction may not be immediately apparent, and the long-term consequences of the circulation of such antibodies may not be known. 16 Importantly, if these immune responses are generated during pregnancy, breast feeding or in a paediatric population, cross-reactivity to endogenous protein has the potential to impact fetal, neonatal or paediatric development. The extent and likelihood of the immune response to longterm exposure to therapeutic protein products in humans is currently unknown.
17
Multiple factors such as patient-related, diseaserelated and product-related factors 13 may have an effect on development of immunogenicity that could then have a significant impact on both efficacy and safety. Patient-related factors affecting immune response include genetic factors and age due to the age-dependent maturation of the immune system. Disease-related factors include an activated immune system due to chronic infection, allergies and autoimmune diseases or an impaired immune system caused by malnutrition, advanced malignant disease or organ failure, pre-existing antibodies or concomitant treatments (e.g. immunomodulators and immunosuppressive therapy). Short-term treatments, the intravenous route of administration and continuous administration may be less immunogenic when compared to long-term treatments, inhalation, intradermal, subcutaneous, intramuscular administration, intermittent treatments, re-exposure or a long treatment-free interval. 16, 18 For example, an INX induction regimen followed by a regular maintenance treatment schedule was associated with lower incidence of ADAs and greater clinical benefit compared to a single dose followed by episodic regimens. 19 Product-related factors such as major modification of the therapeutic protein glycosylation, pegylation or fusion proteins (conjugates between protein and a chemical drug/moiety) may also lead to increased or decreased immunogenicity. In addition, interactions between protein and excipients, impurities from the manufacturing process or packaging may trigger an immune response. 13, 18, 20 As immunogenicity may be altered with changes in manufacturing processes, immunogenicity data are required for licensing of biologicals and biosimilars. 4, 10 Immunogenicity testing of a biosimilar should be conducted using analytical assays with both the biosimilar and reference biologic via a parallel blinded study. The immune response against the product received by each patient is measured using assays capable of detecting antibodies developed against the biosimilar and reference biologic. The incidence, nature of antibodies (e.g. cross-reactivity, target epitopes and neutralising activity) and antibody titres are measured and then assessed in relation to their potential effects on clinical efficacy and safety parameters. 13 The duration of the immunogenicity study depends on the duration of the treatment course, disappearance of the product from the circulation (to avoid antigen interference in the assays) and the time for emergence of humoral immune response (at least 4 weeks when an immunosuppressive agent is used). The duration of follow-up depends on the time course and characteristic of unwanted immune response described for the reference medicinal product. In the case of chronic administration, a 1-year follow up of immunogenicity data is required. Shorter follow-up data pre-authorisation (e.g. 6 months) might be justified based on the immunogenicity profile of the reference product.
Both increased and reduced immunogenicity as compared to the reference biologic would cast doubt on biosimilarity. In a case of reduced immunogenicity, an additional exploratory subgroup analysis of efficacy and safety in those patients that did not develop an antidrug antibody response is required. 13, 20 The incidence, nature of immune response and consequences are assessed using a comparative parallel design (head-to-head) study in treatment-na€ ıve patients. Subsequently, a subset of patients is evaluated in a cross-over study from the reference biologic to the proposed biosimilar to evaluate the risk of hypersensitivity, immunogenicity and other adverse reactions. 20 The NOR-SWITCH clinical trial was the first randomised, double-blind, parallel-group study designed to evaluate safety and efficacy of switching from biologic INX to biosimilar CT-P13 compared with continued treatment with biologic INX in patients with rheumatoid diseases (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), inflammatory bowel disease (Crohn's disease and ulcerative colitis) and chronic plaque psoriasis. The NOR-SWITCH trial demonstrated that a switch from biologic INX to CT-P13 was not inferior to continued treatment with biologic INX. 21 
INDICATION EXTRAPOLATION
Biosimilars, as opposed to generics, cannot be automatically used for all indications approved for the reference biologic. They may be approved for an extrapolated indication (indication which has not been directly assessed in clinical trials) when a biosimilar is believed to have the same mechanisms of action in a different condition and/or at different receptors and is used in similar doses or durations.
2,13,18
As different patient populations and different autoimmune conditions could influence immunogenicity, it is recommended that immunogenicity tests are conducted in patient populations with the highest risk of developing adverse immune reactions, so that any extrapolated indications are for uses and patient populations where a lower risk would be expected, e.g. due to lower dose or shorter duration of use. 1, 4, 18 For example, patients taking immunosuppressants would be less likely to develop immune responses than patients who are not immunocompromised. 20 Furthermore, the extrapolation from the studied route of administration to other routes should be justified. 13 For example, pure red cell aplasia (PRCA) is a potential concern with subcutaneous (SC) use of epoetins in patients with renal anaemia but not with the intravenous (IV) route in anaemia associated with use of chemotherapy. Therefore, extrapolation of immunogenicity data is possible from SC use in patients with renal anaemia to the IV route in the same population or SC use in patients with cancer, but not vice versa. The extrapolation of indications for monoclonal antibodies like INX, is more challenging compared with cytokines and hormones such as epoetin, filgrastim, insulin and growth hormone, due to multiple binding sites and molecular targets, different mechanisms of action, distinct clinical manifestations of diseases, pharmacokinetics, concomitant medications, immunogenicity risk and safety profile. 18 For this reason, the indications for use of a biosimilar may differ in different countries, e.g. INX is approved for a more limited range of indications in Canada than in most other countries. 1, 18 In Canada, extrapolation of indications for the INX biosimilar CT-P13 from rheumatoid arthritis (RA) and ankylosing spondylitis (AS) was allowed for psoriatic arthritis (PsA) and plaque psoriasis (Pso), but not for Crohn's disease (CD) or ulcerative colitis (UC) due to differences between CT-P13 and infliximab observed in vitro, potential differences in the mechanism of action of INX in these conditions and the absence of clinical studies. 12 In comparative clinical trials, patients with RA were treated concomitantly with methotrexate which suppresses the formation of ADA. It should also be noted that INX is used as monotherapy but also in combination with drugs other than methotrexate in PsA, CD, UC and Pso. On the other hand, patients with AS receiving INX monotherapy have historically shown a lower incidence of ADA to INX than patients with Pso, CD or UC. Therefore, patients with RA and AS should not be considered sensitive populations from which to extrapolate immunogenicity data.
18
Consideration should also be given to dosing used for different indications, as this may potentially affect the adverse effects profile. For instance, the original biologic INX is approved for use in RA, CD and UC at a dose up to 10 mg/kg every 8 weeks. Therefore, the dose of biosimilar CT-P13 studied in the comparative trial for RA was 3 mg/kg every 8 weeks. Health Canada approved CT-P13 for use in RA at the dose studied in the comparative trial. 18 
NAMING AND LABELLING OF BIOSIMILARS
Currently, there is no consensus worldwide on naming conventions for biosimilars. 8, 22 In Europe, the labelling of a biosimilar is the same as for the reference biologic and summary of product characteristics (SmPC) is a copy of the SmPC of the biologic's. 24 The WHO indicated that use of identical non-proprietary names may lead to inadvertent switching between the reference biologic and biosimilars. 8 Currently, the same INN is assigned to the biosimilar that has the identical amino acid sequence (nonglycosylated biologics) and a unique prefix or suffix is assigned to the root INN of the reference biologics for glycosylated biologics and biosimilars (e.g. a Greek letter suffix to indicate different glycosylation patterns, e.g. epoetin alfa). 8 In addition, the WHO guidelines also recommend prescribing information for biosimilars to clearly state the omitted indications and the reasons for exclusion of indications. 22, 23 Some groups have advocated for a non-proprietary name distinguishable from the reference product to avoid difficulties tracing and addressing adverse events. The major disadvantage of this system is that it could assume that the biosimilar might have a different mechanism of action and efficacy profile compared to the reference product. 8 In 2014, the WHO INN for Pharmaceutical Substances Expert Group suggested a two-part naming system for biosimilars -the first part is the INN and the second part is a four-letter biological qualifier (BQ) 24 which is randomly assigned. The adoption of the BQ scheme is voluntary and is intended to assist in the identification of biological substances for prescribing, dispensing, pharmacovigilance and globally transferring prescriptions. 24 In Australia, the TGA supports the WHO program on INN, and biosimilars with products labelled using the Australian biological name without a specific biosimilar identifier suffix. 7 
INTERCHANGEABILITY AND SUBSTITUTION
The standard bioequivalence approach to generic medicines applied to chemical products is not appropriate for biological medicines as the structure of a biosimilar medicine is not identical to the structure of the biological reference and therefore the immunogenicity profile may be different. This may preclude switching between products. 25 In addition, automatic substitution may affect traceability of the product which is necessary in the case of adverse events. Moreover, repeated switches between the biosimilar and biologic or between the biosimilars may increase immunogenicity. 4 Due to the lack of data on long-term efficacy and safety of biosimilars and due to potential lack of traceability, automatic substitution may be considered problematic. However, recommendations for interchangeability and substitution are not uniform and differ between countries. 2, 3, 12, 25 In 2015, the Pharmaceutical Benefits Advisory Committee (PBAC) made a world-first recommendation to allow clinicians and pharmacists to give patients the option of substituting an expensive biologic medicine where there is a less costly replacement or biosimilar available. 24 In Australia, the evaluation of biosimilars is conducted by the TGA using quality, safety and efficacy data to determine whether the biosimilar is equally as safe and effective as the reference biologic. The TGA has adopted a number of European guidelines and the International Conference on Harmonisation (ICH) guideline on the assessment of comparability. 7 Following approval by the TGA, the PBAC evaluates the biosimilar for addition to the Pharmaceutical Benefit Scheme (PBS). The evaluation of biosimilars in Australia is conducted on a case-by-case basis as to whether to permit substitution by a doctor or pharmacist. 26 
CONCLUSION
Biosimilars can be highly similar to their biologic reference, with comparable safety and efficacy, and can be manufactured at a lower cost. They have the potential to increase competition, reduce costs and increase treatment options and improve patient access to therapies. The unresolved concerns are interchangeability, automatic substitution, nomenclature, indication extrapolation and parameters for ongoing pharmacovigilance. Pre-clinical and clinical data should be used to evaluate efficacy, safety, comparability and interchangeability of biosimilars with their reference biologic to facilitate informed decision-making for safe, effective and economical use of these novel therapies.
